Cargando…
Immunogenicity of the COVID-19 BNT162b2 vaccine in adolescents and young adults with cystic fibrosis
Data regarding immunogenicity of SARS-CoV-2 BNT162b2 vaccine in cystic fibrosis (CF) patients are limited. We prospectively measured total (TAbs-RBD; U/ml) and neutralizing (NAbs-RBD; %) antibodies of SARS-CoV-2 spike-receptor binding domain (RBD) protein in 33 CF patients and 66 healthy controls wi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Cystic Fibrosis Society. Published by Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008191/ https://www.ncbi.nlm.nih.gov/pubmed/35461782 http://dx.doi.org/10.1016/j.jcf.2022.04.004 |
_version_ | 1784686994731827200 |
---|---|
author | Michos, Athanasios Filippatos, Filippos Tatsi, Elizabeth-Barbara Dellis, Charilaos Efthymiou, Vasiliki Zarkada, Ioanna Troupi, Evgenia Syriopoulou, Vasiliki Loukou, Ioanna |
author_facet | Michos, Athanasios Filippatos, Filippos Tatsi, Elizabeth-Barbara Dellis, Charilaos Efthymiou, Vasiliki Zarkada, Ioanna Troupi, Evgenia Syriopoulou, Vasiliki Loukou, Ioanna |
author_sort | Michos, Athanasios |
collection | PubMed |
description | Data regarding immunogenicity of SARS-CoV-2 BNT162b2 vaccine in cystic fibrosis (CF) patients are limited. We prospectively measured total (TAbs-RBD; U/ml) and neutralizing (NAbs-RBD; %) antibodies of SARS-CoV-2 spike-receptor binding domain (RBD) protein in 33 CF patients and 66 healthy controls with median age (IQR): 19.6 (17.6–24.3) years and 31 (29–36) years, respectively and investigated possible associations with epidemiological and clinical parameters. Compared to healthy controls, CF patients had higher levels of TAbs-RBD and NAbs-RBD after both doses (P-value < 0.001). One month after the second dose, CF patients and controls had TAbs-RBD: median (IQR): 3396 (2443) and 1452 (1231) U/ml, respectively. Similarly, the NAbs-RBD (%) were: 97.30 (1.00) and 95.70 (3.71) %, respectively. CF patients also had fewer local and systemic adverse events (AEs) (P-value < 0.001). Among CF patients, no significant differences in immunogenicity were detected regarding the phenotype, genotype, medications, or severity of the disease. BNT162b2 vaccine was immunogenic with limited reactogenicity in CF patients regardless of the phenotype or severity of disease. |
format | Online Article Text |
id | pubmed-9008191 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | European Cystic Fibrosis Society. Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90081912022-04-14 Immunogenicity of the COVID-19 BNT162b2 vaccine in adolescents and young adults with cystic fibrosis Michos, Athanasios Filippatos, Filippos Tatsi, Elizabeth-Barbara Dellis, Charilaos Efthymiou, Vasiliki Zarkada, Ioanna Troupi, Evgenia Syriopoulou, Vasiliki Loukou, Ioanna J Cyst Fibros Short Communication Data regarding immunogenicity of SARS-CoV-2 BNT162b2 vaccine in cystic fibrosis (CF) patients are limited. We prospectively measured total (TAbs-RBD; U/ml) and neutralizing (NAbs-RBD; %) antibodies of SARS-CoV-2 spike-receptor binding domain (RBD) protein in 33 CF patients and 66 healthy controls with median age (IQR): 19.6 (17.6–24.3) years and 31 (29–36) years, respectively and investigated possible associations with epidemiological and clinical parameters. Compared to healthy controls, CF patients had higher levels of TAbs-RBD and NAbs-RBD after both doses (P-value < 0.001). One month after the second dose, CF patients and controls had TAbs-RBD: median (IQR): 3396 (2443) and 1452 (1231) U/ml, respectively. Similarly, the NAbs-RBD (%) were: 97.30 (1.00) and 95.70 (3.71) %, respectively. CF patients also had fewer local and systemic adverse events (AEs) (P-value < 0.001). Among CF patients, no significant differences in immunogenicity were detected regarding the phenotype, genotype, medications, or severity of the disease. BNT162b2 vaccine was immunogenic with limited reactogenicity in CF patients regardless of the phenotype or severity of disease. European Cystic Fibrosis Society. Published by Elsevier B.V. 2022-05 2022-04-14 /pmc/articles/PMC9008191/ /pubmed/35461782 http://dx.doi.org/10.1016/j.jcf.2022.04.004 Text en © 2022 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Short Communication Michos, Athanasios Filippatos, Filippos Tatsi, Elizabeth-Barbara Dellis, Charilaos Efthymiou, Vasiliki Zarkada, Ioanna Troupi, Evgenia Syriopoulou, Vasiliki Loukou, Ioanna Immunogenicity of the COVID-19 BNT162b2 vaccine in adolescents and young adults with cystic fibrosis |
title | Immunogenicity of the COVID-19 BNT162b2 vaccine in adolescents and young adults with cystic fibrosis |
title_full | Immunogenicity of the COVID-19 BNT162b2 vaccine in adolescents and young adults with cystic fibrosis |
title_fullStr | Immunogenicity of the COVID-19 BNT162b2 vaccine in adolescents and young adults with cystic fibrosis |
title_full_unstemmed | Immunogenicity of the COVID-19 BNT162b2 vaccine in adolescents and young adults with cystic fibrosis |
title_short | Immunogenicity of the COVID-19 BNT162b2 vaccine in adolescents and young adults with cystic fibrosis |
title_sort | immunogenicity of the covid-19 bnt162b2 vaccine in adolescents and young adults with cystic fibrosis |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008191/ https://www.ncbi.nlm.nih.gov/pubmed/35461782 http://dx.doi.org/10.1016/j.jcf.2022.04.004 |
work_keys_str_mv | AT michosathanasios immunogenicityofthecovid19bnt162b2vaccineinadolescentsandyoungadultswithcysticfibrosis AT filippatosfilippos immunogenicityofthecovid19bnt162b2vaccineinadolescentsandyoungadultswithcysticfibrosis AT tatsielizabethbarbara immunogenicityofthecovid19bnt162b2vaccineinadolescentsandyoungadultswithcysticfibrosis AT dellischarilaos immunogenicityofthecovid19bnt162b2vaccineinadolescentsandyoungadultswithcysticfibrosis AT efthymiouvasiliki immunogenicityofthecovid19bnt162b2vaccineinadolescentsandyoungadultswithcysticfibrosis AT zarkadaioanna immunogenicityofthecovid19bnt162b2vaccineinadolescentsandyoungadultswithcysticfibrosis AT troupievgenia immunogenicityofthecovid19bnt162b2vaccineinadolescentsandyoungadultswithcysticfibrosis AT syriopoulouvasiliki immunogenicityofthecovid19bnt162b2vaccineinadolescentsandyoungadultswithcysticfibrosis AT loukouioanna immunogenicityofthecovid19bnt162b2vaccineinadolescentsandyoungadultswithcysticfibrosis |